PAREXEL Chairman And CEO Named 2014 Immigrant Entrepreneur of the Year in Life Sciences - San Diego, California News Station - KFMB Channel 8 - cbs8.com

PAREXEL Chairman And CEO Named 2014 Immigrant Entrepreneur of the Year in Life Sciences

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE PAREXEL International

BOSTON, May 9, 2014 /PRNewswire/ -- PAREXEL International (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today announced that its Chairman and CEO, Josef von Rickenbach, was named 2014 Immigrant Entrepreneur of the Year in Life Sciences by the Immigrant Learning Center of Malden, Mass.  He received the award May 8, 2014, during the third annual Immigrant Entrepreneur Awards Dinner in Cambridge, Mass.

A native of Switzerland, Mr. von Rickenbach earned a B.A. in Business Economics from the School of Business at the Lucerne University of Applied Sciences.  After graduating from Harvard Business School in 1981, he co-founded PAREXEL in Cambridge in 1982 as a biopharmaceutical regulatory consulting company.  Over 30 years, he transformed the company into one of the world's top biopharmaceutical service providers, leading PAREXEL through its IPO, multiple public offerings, and over 35 mergers and acquisitions.  In particular, he pioneered a multidisciplinary and systems-oriented approach to outsourced clinical research, bringing efficiencies, scalability and standardization to global drug development.

Headquartered in Waltham, Mass., PAREXEL today has more than 15,000 employees and conducts clinical trials in over 100 countries. The company recorded total service revenue of $1.7 billion in 2013, and ranked fifth in the Boston Globe's "Globe 100" list of best performing public companies in the state.

Mr. von Rickenbach's extensive industry expertise puts him at the forefront of drug development and management leadership.  In 2013, he received the Henri Termeer Innovative Leadership Award from the Massachusetts Biotechnology Council (MassBio). He is a noted contributor to the New England business community, serving on the Board of Directors of NEHI (Network for Excellence in Health Innovation) and on the Health Policy and Management Executive Council of the Harvard School of Public Health.  Additionally, he is a Vice Chair of CEOs Against Cancer, sponsored by the American Cancer Society New England Chapter, and holds board positions on several nonprofit organizations.

"I am grateful for the opportunity to have launched a business in Massachusetts.  The state has provided us access to outstanding scientific expertise, renowned educational institutions and emerging biopharmaceutical and high technology industries that helped fuel our growth," said Mr. von Rickenbach.  "I am particularly honored by this recognition, which also reflects the collective contributions of our thousands of employees around the world."

The annual Immigrant Entrepreneur Awards program is sponsored by the Immigrant Learning Center (ILC) of Malden, Mass., a nonprofit organization that helps immigrants and refugees become successful workers, parents and community members through direct service programs and public education. Their direct service program provides free year-round English classes to immigrant and refugee adults in Greater Boston.  For more information, visit http://www.ilctr.org.

About PAREXEL International

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 75 locations in 50 countries around the world, and has 15,335 employees.  For more information about PAREXEL International visit www.PAREXEL.com.

PAREXEL and "Your Journey.  Our Mission." are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates.

This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand.   For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should,"  "targets," and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions, and to integrate newly acquired businesses including the recent acquisitions of LIQUENT, Inc. and HERON, Inc., or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.   Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2013 as filed with the SEC on January 31, 2014, which "Risk Factors" discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

Contacts:
Diana Martin, Vice President, Corporate Communications
PAREXEL International
Tel: +1 781-434-5516
Email: Diana.Martin@PAREXEL.com

Matthew Briggs
PAN Communications
Tel: +1 617-502-4300
Email: PAREXEL@pancomm.com

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and Midwest Television, Inc. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.